Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Start Time: 16:30 January 1, 0000 5:00 PM ET Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2020 Earnings Conference Call July 30, 2020, 16:30 PM ET Company Participants Jack Peurach - President and CEO Jack Glenn - CFO Bill Shaw - Chief Commercial Officer David Carey - IR, Lazar Partners Ltd. Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Nathan Weinstein - Aegis Capital Operator Greetings, and welcome to Ekso Bionics Second Quarter 2020 Financial Results Call. At this time, all partic ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2020 Results Earnings Conference Call April 30, 2020 4:30 PM ET Company Participants David Carey - Investor Relations, Lazar Partners Ltd. Jack Peurach - President and Chief Executive Officer Bill Shaw - Chief Commercial Officer Jack Glenn - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corp. Operator Greetings and welcome to the Ekso Bionics First Quarter 2020 Financial Results Conference C ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Ekso Bionics' unaudited condensed consolidated financial statements are presented, highlighting liquidity challenges and substantial doubt regarding its going concern status [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased from **$21.9 million** to **$16.9 million**, driven by reduced cash and receivables, while total liabilities and stockholders' equity also declined Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2020 (unaudited) | December 31, 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $8,516 | $10,872 | | Accounts receivable, net | $2,658 | $5,208 | | Total current assets | $14,062 | $18,807 | | **Total assets** | **$16,944** | **$21,915** | | **Liabilities & Equity** | | | | Total current liabilities | $7,550 | $7,832 | | Warrant liabilities | $1,788 | $4,307 | | **Total liabilities** | **$11,716** | **$15,118** | | **Total stockholders' equity** | **$5,228** | **$6,797** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Q1 2020 revenue significantly decreased to **$1.5 million**, resulting in a **$2.5 million** net loss, an improvement from Q1 2019 due to a gain on warrant revaluation Q1 2020 vs. Q1 2019 Statement of Operations (in thousands, except per share) | Metric | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Revenue | $1,468 | $3,616 | | Gross Profit | $637 | $1,599 | | Total Operating Expenses | $5,418 | $6,511 | | Loss from Operations | $(4,781) | $(4,912) | | Gain (loss) on revaluation of warrant liabilities | $2,519 | $(1,122) | | **Net Loss** | **$(2,534)** | **$(6,551)** | | Basic and diluted net loss per share | $(0.44) | $(1.51) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$1.7 million** in Q1 2020, with the cash balance decreasing by **$2.4 million** to **$8.5 million** by quarter-end Cash Flow Summary (in thousands) | Activity | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | $(1,722) | $(5,177) | | Net cash used in investing activities | $0 | $(7) | | Net cash (used in) provided by financing activities | $(589) | $6,769 | | **Net increase (decrease) in cash** | **$(2,356)** | **$1,581** | | Cash at end of period | $8,516 | $9,236 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes provide critical context, addressing liquidity, going concern uncertainty, China JV status, debt obligations, and subsequent events like a PPP loan and loan amendment - The company's cash on hand is not sufficient to fund operations for the next twelve months, which raises **substantial doubt** about its ability to continue as a going concern. As of March 31, **2020**, cash was **$8.5 million**, but restricted cash requirements reduced effective unrestricted cash to an estimated **$5.0 million**[31](index=31&type=chunk)[205](index=205&type=chunk) - On March 24, **2020**, the company effected a 1-for-15 reverse stock split of its common stock to regain compliance with Nasdaq's minimum bid price requirement[32](index=32&type=chunk)[120](index=120&type=chunk) - The company's China joint venture is under review by the Committee on Foreign Investment in the United States (CFIUS), which has imposed interim measures temporarily suspending the company's contributions and integration activities for the JV[99](index=99&type=chunk) - Subsequent to the quarter end, the company received a **$1.1 million** unsecured loan under the Paycheck Protection Program (PPP) and amended its term loan to **defer principal payments** for three months[173](index=173&type=chunk)[174](index=174&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=36&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a **59%** Q1 **2020** revenue decline due to COVID-19, a **17%** operating expense reduction, and reiterates the need for significant additional financing to address going concern issues Q1 2020 vs Q1 2019 Results of Operations (in thousands) | Metric | Q1 2020 | Q1 2019 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Revenue | $1,468 | $3,616 | $(2,148) | (59)% | | Gross Profit | $637 | $1,599 | $(962) | (60)% | | Total Operating Expenses | $5,418 | $6,511 | $(1,093) | (17)% | | Net Loss | $(2,534) | $(6,551) | $4,017 | (61)% | - The decrease in revenue was primarily driven by the impact of the COVID-19 pandemic, as customers shifted priorities and delayed orders that are typically booked late in the quarter[193](index=193&type=chunk) - The reduction in operating expenses reflects company-wide initiatives implemented in the prior year and improved operational efficiencies, including lower headcount and reduced marketing and R&D costs[197](index=197&type=chunk)[198](index=198&type=chunk)[199](index=199&type=chunk) - Management states that based on current cash resources, the company has sufficient funds to operate until the end of the fourth quarter of **2020**, but will require significant additional financing to continue beyond that[208](index=208&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks, including foreign currency exchange rate fluctuations from international operations, but inflation has not had a material effect - The company is exposed to exchange rate risk due to its business in foreign countries, including subsidiaries in Germany and Singapore[220](index=220&type=chunk) - Management does not believe inflation has had a material effect on the business, but notes that an inability to offset significant inflationary pressures with price increases could harm future results[219](index=219&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, **2020**, with no material changes to internal control over financial reporting - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of the end of the period[222](index=222&type=chunk) - No changes occurred in the company's internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal controls[225](index=225&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) The company is not subject to any pending legal proceedings that would materially impact its financial condition or results of operations - As of the filing date, the company is not the subject of any pending legal proceedings, and management is not aware of any threatened proceedings that would have a material impact[227](index=227&type=chunk) [Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) Material risk factors include COVID-19 impacts, potential China JV restrictions from CFIUS review, and risks associated with the recent reverse stock split - The COVID-19 outbreak could **materially adversely affect** financial results due to business disruptions, supply chain delays, reduced customer demand, and potential impacts on the company's workforce and ability to raise capital[229](index=229&type=chunk)[230](index=230&type=chunk) - The company's China JV is under review by CFIUS, which has imposed interim measures suspending contributions. An adverse outcome could restrict technology transfer or compel the company to abandon the JV[237](index=237&type=chunk)[238](index=238&type=chunk) - The 1-for-15 reverse stock split effected on March 24, **2020**, has **decreased the liquidity** of the common stock. While the company regained compliance with Nasdaq's minimum bid price rule, there is **no assurance it can maintain compliance** in the future[241](index=241&type=chunk)[243](index=243&type=chunk)[244](index=244&type=chunk) [Other Information](index=47&type=section&id=Item%205.%20Other%20Information) The company amended its loan agreement, **deferring principal payments** for three months and revising the liquidity covenant to a **minimum cash balance** requirement - The company amended its loan agreement to **defer principal payments** for three months starting in May **2020**, with interest-only payments required during this period[245](index=245&type=chunk) - The loan's liquidity covenant was changed from a 'three-months of monthly cash burn' requirement to a **minimum cash balance** equal to the outstanding loan amount[245](index=245&type=chunk) [Exhibits](index=48&type=section&id=Item%206.%20Exhibits) Exhibits filed with Form 10-Q include the second amendment to the loan agreement and CEO/CFO certifications - Key exhibits filed include the Second Amendment to the Loan and Security Agreement with Western Alliance Bank and certifications from the CEO and CFO[250](index=250&type=chunk)[249](index=249&type=chunk)[251](index=251&type=chunk)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Matt Steinberg - Lazar Partners Jack Peurach - President, CEO & Director William Shaw - Chief Commercial Officer John Glenn - CFO & Secretary Conference Call Participants Dennis Pak - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corporation Operator Greetings and welcome to the Ekso Bionics Fourth Quarter 2019 Financial Results Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value EKSO Nasdaq Stock Market LLC (Nasdaq Capital Market) WASHINGTON, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics H ...

Ekso Bionics Holdings Inc (NASDAQ:EKSO) Q3 2019 Results Conference Call October 30, 2019 4:30 PM ET Company Participants David Carey - Investor Relations Jack Peurach - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Bill Shaw - Chief Commercial Officer Conference Call Participants Craig Bijou - Cantor Fitzgerald Swayampakula Ramakanth - HC Wainwright Nathan Weinstein - Aegis Capital Corp Operator Greetings and welcome to Ekso Bionics Third Quarter 2019 Financial Results Conferenc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Financial Data and Key Metrics Changes - In Q2 2019, revenue was $3.3 million, an increase from $3.0 million in Q2 2018, reflecting a growth of approximately 10% [10][20] - Gross margins expanded to approximately 48%, an increase of 15 percentage points from the same quarter last year [10][22] - Operating expenses decreased by more than 18% to $6.7 million compared to $8.2 million in Q2 2018 [10][23] - Net loss for the quarter was $3.1 million or $0.04 per share, compared to a net loss of $8 million or $0.13 per share in Q2 2018 [10][24] Business Line Data and Key Metrics Changes - EksoHealth revenue increased by approximately 18% compared to Q2 2018, driven by higher sales in the U.S. and improved rental-to-sale conversions [11] - The cumulative rental-to-sale conversion rate in the U.S. rose to 84%, up from 76% in the first quarter [11] - EksoWorks revenue decreased to approximately $415,000 from $555,000 in the same period last year, primarily due to delayed customer purchasing decisions [21] Market Data and Key Metrics Changes - U.S. market growth was strong, but performance in EMEA and APAC was softer, leading to adjustments in the European organization to better support distribution partners [15] - The company is optimistic about expanding its market opportunities with larger network operators in the U.S. [12] Company Strategy and Development Direction - The company aims to amplify human motion through advanced robotics in both medical and industrial applications [8] - A new product, the EksoUE, was introduced for upper extremity rehabilitation, expected to be available by the end of the year [16] - The company is committed to developing new technologies to enhance human mobility while optimizing its cost structure [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of EMEA and APAC markets despite current performance challenges [15] - The company expects to continue strengthening its customer pipeline with an expanded sales and marketing team [27] Other Important Information - Cash used in operating activities in Q2 2019 was $4.5 million, down from $5.2 million in Q1 2019, with a cash balance of $13.3 million as of June 30, 2019 [26] - The company completed treating all 30 patients in the WISE study and expects to report complete study data by the end of 2019 [27] Q&A Session Summary Question: What were the key drivers of revenue growth in Q2? - The revenue growth was primarily driven by higher U.S. sales and increased rental-to-sale conversions for Ekso GT units [27] Question: How is the company addressing the performance in EMEA and APAC? - The company is making changes to its European organization to better support distribution partners and expand customer awareness [15][27] Question: What are the expectations for future product launches? - The company plans to continue developing innovative products, including the recently announced EksoUE, to enhance rehabilitation solutions [16][27]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...